Allar, Jerusalem

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Retrieved on: 
Thursday, July 27, 2023
Pomerantz, Therapy, News, Allar, Jerusalem, Security (finance)

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).

Key Points: 
  • NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Retrieved on: 
Wednesday, July 19, 2023
Exercise, Pomerantz, Therapy, News, Allar, Jerusalem, Security (finance)

NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).

Key Points: 
  • NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Retrieved on: 
Sunday, July 9, 2023
Exercise, Pomerantz, Therapy, News, Allar, Jerusalem, Security (finance)

NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).

Key Points: 
  • NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

Retrieved on: 
Wednesday, April 19, 2023
Exercise, Therapy, Telephone, Free File, Sale, Prospectus, Form, Madison Avenue, Security (finance), Allar, Jerusalem

The warrants will have an exercise price of $0.85 per share, will be exercisable immediately and will expire five years from the initial exercise date.

Key Points: 
  • The warrants will have an exercise price of $0.85 per share, will be exercisable immediately and will expire five years from the initial exercise date.
  • The closing of the offering is expected to occur on or about April 21, 2023, subject to the satisfaction of customary closing conditions.
  • A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
  • The offering is being made only by means of a prospectus forming part of the effective registration statement.

Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

Retrieved on: 
Tuesday, April 11, 2023
Abstract, Therapy, McCormick Place, Cisplatin, ASCO, Hospital, American Society of Clinical Oncology, Patient, Annual general meeting, Poster, Society, Allar, Jerusalem, Pharmaceutical industry

Researchers will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago.

Key Points: 
  • Researchers will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago.
  • The poster shows the final data from a phase 2 study evaluating the ability of the DRP® companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis®, a targeted liposomal formulation of cisplatin.
  • Allarity conducted the study in collaboration with investigators at hospitals in Denmark, as well as its CRO Smerud Medical Research International AS.
  • The poster presentation details are as follows:
    ASCO will publish the official abstracts on its meeting website in advance of the ASCO Annual Meeting at 5:00 p.m.

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022
D, PARP, Literature, Research and development, RNA, Administration, G&A, R, Partnership, Therapy, Patient, Doxorubicin, Research, Public expenditure, Ixabepilone, Cisplatin, GBM, Glioblastoma, Cancer, Allar, Jerusalem, Ovarian cancer, Clinical trial, Pharmaceutical industry, Cryptocurrency

Cambridge, MA U.S.A. (November 15, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Cambridge, MA U.S.A. (November 15, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022.
  • Balance Sheet: As of September 30, 2022, Allaritys cash was $3.9 million, as compared to $19.6 million as of December 31, 2021.
  • Net Loss: Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

EQS-News: Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

Retrieved on: 
Saturday, October 22, 2022
GBM, PARP, EGFR, Therapy, MYGN, Science, NRAS, Food and Drug Administration, Novartis, NYSE, NASDAQ, Neoplasm, Allar, Jerusalem, Patient, Drug development, Doxorubicin, Foundation Medicine, Research, Ixabepilone, Nasdaq, KRAS, Cancer, Food, Partnership, Company, Colorectal cancer, Safety, Advertising, Cisplatin, Association for Molecular Pathology v. Myriad Genetics, Inc., NVS, FDA, Gene, Ovarian cancer, Biomarker, Glioblastoma, Pharmaceutical industry, Medical imaging, Vaccine

Once brought into its pipeline , Allarity uses its DRP platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach.

Key Points: 
  • Once brought into its pipeline , Allarity uses its DRP platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach.
  • Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.
  • Allaritys Drug Response Predictor (DRP) platform is a unique bioanalytical platform that can create drug-specific predictive diagnostics for a wide range of cancer treatments.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Global FLT3 Inhibitors Market Research Report 2022: Focus on Commercialized Therapy & Potential Pipeline Products - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
General Health, Pharmaceutical, Health, Investigational New Drug, Fibroblast growth factor receptor 1, NDA, Allar, Jerusalem, Cancer, Research, Abbreviated New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RCC, Therapy, IND, Benchmarking, AML, Incidence, New Drug Application, Novartis, Food, Renal cell carcinoma, Diagnosis, Acute myeloid leukemia, Investment, Region, Lymphatic system, Classification, FLT3, Daiichi Sankyo, Biology, FDA, CAGR, CRL, Adult, Crenolanib, Country, Name, Endpoint security, Industry, Drug development, Astellas Pharma, Growth, Patient, Pharmaceutical industry, Gilteritinib, Limited

The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The current study aims to assess the global FLT3 inhibitors market by focusing on the marketed and potential pipeline therapies.
  • Increasing investments in the research and development of drug manufacturing are one of the major opportunities in the global FLT3 inhibitors market.
  • The growing interest of the pharmaceutical industry in the therapeutic potential for treating blood cancers with FLT3 positive mutations has been a catalyst for the progress of the global FLT3 inhibitors market.

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Retrieved on: 
Monday, January 3, 2022
MA, NDA, Cancer, Clinical trial, Cisplatin, FDA, File, RNA, Doxorubicin, Ixabepilone, Glioblastoma, RCC, Survival, Ovarian cancer, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Prostate cancer, Partnership, PARP, CEO, Therapy, PMA, Dana–Farber Cancer Institute, Patient, Nasdaq, Program, Adult, Drug development, Allar, Jerusalem, Renal cell carcinoma, Time, Literature, GBM, Osteosarcoma, Fibroblast growth factor receptor, Pharmaceutical industry, Fibroblast growth factor receptor 1

Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers.

Key Points: 
  • Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers.
  • Oncoheroes will take responsibility for pediatric cancer clinical development activities for both clinical-stage therapeutics.
  • If Allarity does not re-acquire the pediatric field rights, it will further receive certain clinical/regulatory milestone payments and royalties on sales of stenoparib and dovitinib in the pediatric cancer market from Oncoheroes.
  • Steve R. Carchedi, CEO of Allarity Therapeutics, commented, We are very pleased to partner with Oncoheroes Biosciences to advance both dovitinib and stenoparib as potential new therapeutic options for the personalized treatment of children and adolescents with cancer.

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Retrieved on: 
Thursday, November 11, 2021
Cancer, Therapy, Breast, University of Arizona, APP, Clinical trial, Fibroblast growth factor receptor, COVID-19, National Institute, Laboratory, Fatality, NIH, NIAID, Allar, Jerusalem, Dana–Farber Cancer Institute, Severe acute respiratory syndrome coronavirus 2, Research, Social media, Forward-looking statement, Cisplatin, MBio, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doxorubicin, Patient, CEO, Disease, Degenerative disease, Goal, Northern Arizona University, PARP, Vaccine, Virus, Drug discovery, National Institutes of Health, DNA, Infection, Prostate cancer, RNA, Ixabepilone, Ovarian cancer, Renal cell carcinoma, Company, Pathogen, Antibody, Breast cancer, Center, Nasdaq, Poly (ADP-ribose) polymerase, Pharmaceutical industry

Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (British variant),

Key Points: 
  • Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (British variant),
    Allarity Therapeutics is planning to submit findings to U.S. National Institutes of Health (NIH)
    Hrsholm, Denmark (November 11, 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant).
  • In addition, the Company announced, on August 5, 2021, further pre-clinical tests that had shown stenoparib also inhibits SARS-Cov-2 variants, including alpha variant B.1.1.7 (British variant), beta variant B.1351 (South African variant), and gamma variant P.1 (Brazilian variant).
  • The additional pre-clinical results announced today show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells.
  • The delta variant used for the experiments carries an additional deletion in ORF7a, a rapidly spreading mutation.